Company Update (NYSE:OPK): Two Reports on Opko Health Inc.’s hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the ESPE Conference
Opko Health Inc. (NYSE:OPK) announced that additional data from OPKO’s hGH-CTP pediatric Phase 2 clinical trials summarized in two abstracts entitled, “12 month Safety and efficacy of a weekly long-acting growth hormone (GH, MOD-4023) compared to daily recombinant human GH (rh)GH) therapy in pre-pubertal growth hormone deficient children; Phase 2 study – Study CP-4-004 Summary” and “Pharmacokinetic (PK) and Pharmacodynamics (PD) Modeling of MOD 4023 (a long-acting human growth hormone (hGH)) in Growth Hormone Deficient (GHD) Children” has been selected for oral presentation at the upcoming 54th Annual Meeting of the European Society for Paediatric Endocrinology taking place in Barcelona, Spain from October 1-3.
The data to be presented include results for 52 patients completing twelve months of weekly treatment with hGH-CTP. This phase 2 study was a one year, dose finding study administering hGH-CTP to growth hormone deficient children once a week using Genotropin® administered daily as a comparator arm. The twelve months data confirm comparable response of hGH-CTP to Genotropin® injected daily as reflected by the twelve months serum insulin-like growth factor-1 standard deviation score (IGF-1SDS) profile, annual height velocity (HV), height velocity standard deviation score (HV SDS) and safety profile. The data affirm the selection of an optimal dose that would be used to demonstrate non-inferiority compared to daily administered hGH in the upcoming phase 3 study.
OPKO oral presentations will be held at the Growth-promoting therapies session on Saturday, October 3, 2015 at 9:55 AM and 10:05 AM. (Original Source)
Shares of Opko Health opened today at $16.17 and are currently trading down at $16.08. OPK has a 1-year high of $19.20 and a 1-year low of $8.02. The stock’s 50-day moving average is $16.23 and its 200-day moving average is $15.04.
On the ratings front, Oppenheimer analyst Rohit Vanjani maintained a Hold rating on OPK, in a report issued on May 12. According to TipRanks.com, Vanjani has a total average return of 41.9%, a 79.5% success rate, and is ranked #10 out of 3724 analysts.
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.